RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Circular EZH2-encoded EZH2-92aa mediates immune evasion in glioblastoma via inhibition of surface NKG2D ligands.
Circular EZH2-encoded EZH2-92aa mediates immune evasion in glioblastoma via inhibition of surface NKG2D ligands.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
胶质母细胞瘤(GBM)是一种高度侵袭性的原发性脑肿瘤,对几乎所有可用治疗均耐药,包括自然杀伤(NK)细胞免疫治疗。然而,介导GBM中NK细胞逃逸的因素在很大程度上仍不清楚。
在此,我们报道EZH2-92aa,一种由环状EZH2编码的蛋白,在GBM中过表达,并诱导GBM干细胞(GSCs)对NK细胞的免疫逃逸。EZH2-92aa受DEAD-box解旋酶3(DDX3)正向调控,直接结合主要组织相容性复合体I类多肽相关序列A/B(MICA/B)启动子并抑制其转录;它还通过稳定EZH2间接抑制UL16结合蛋白(ULBP)转录。GSCs中NK group 2D配体(NKG2DLs,包括MICA/B和ULBPs)的下调介导了NK细胞耐药。
此外,稳定敲低EZH2-92aa在体外和体内增强了NK细胞介导的GSC清除,并与抗PD1治疗产生协同作用。我们的结果突出了EZH2-92aa在抑制GBM中NK细胞反应方面的免疫抑制功能,以及靶向EZH2-92aa用于NK细胞导向免疫治疗的临床潜力。
Glioblastoma (GBM) is a highly aggressive primary brain tumour and is resistant to nearly all available treatments, including natural killer (NK) cell immunotherapy.
However, the factors mediating NK cell evasion in GBM remain largely unclear.
Here, we report that EZH2-92aa, a protein encoded by circular EZH2, is overexpressed in GBM and induces the immune evasion of GBM stem cells (GSCs) from NK cells.
Positively regulated by DEAD-box helicase 3 (DDX3), EZH2-92aa directly binds the major histocompatibility complex class I polypeptide-related sequence A/B (MICA/B) promoters and represses their transcription; it also indirectly represses UL16-binding protein (ULBP) transcription by stabilizing EZH2. The downregulation of NK group 2D ligands (NKG2DLs, including MICA/B and ULBPs) in GSCs mediates NK cell resistance.
Moreover, stable EZH2-92aa knockdown enhances NK cell-mediated GSC eradication in vitro and in vivo and synergizes with anti-PD1 therapy.
Our results highlight the immunosuppressive function of EZH2-92aa in inhibiting the NK cell response in GBM and the clinical potential of targeting EZH2-92aa for NK-cell-directed immune therapy.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。